ImmunoGen, Inc. (NASDAQ:IMGN) has a beta value of 1.72 and has seen 3,668,157 shares traded in the last trading session. The company, currently valued at $1.12 Billion, closed the last trade at $5.99 per share which meant it lost -$0.06 on the day or -0.99% during that session. The IMGN stock price is -18.03% off its 52-week high price of $7.07 and 67.45% above the 52-week low of $1.95. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.09 Million shares traded. The 3-month trading volume is 2.75 Million shares.
The consensus among analysts is that ImmunoGen, Inc. (IMGN) is an Overweight stock at the moment, with a recommendation rating of 2.1. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 4 out of 9 have rated it as a Hold, with 5 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.12.
ImmunoGen, Inc. (NASDAQ:IMGN) trade information
Despite being -0.99% in the red today, the stock has traded in the green over the last five days, with the highest price hit on Friday, Nov 20 when the IMGN stock price touched $6.15-2 or saw a rise of 2.6%. Year-to-date, ImmunoGen, Inc. shares have moved 17.34%, while the 5-day performance has seen it change 2.04%. Over the past 30 days, the shares of ImmunoGen, Inc. (NASDAQ:IMGN) have changed 14.1%. Short interest in the company has seen 18.72 Million shares shorted with days to cover at 6.81.
Wall Street analysts have a consensus price target for the stock at $9.25, which means that the shares’ value could jump 54.42% from current levels. The projected low price target is $5.5 while the price target rests at a high of $14. In that case, then, we find that the current price level is +133.72% off the targeted high while a plunge would see the stock lose -8.18% from current levels.
ImmunoGen, Inc. (IMGN) estimates and forecasts
10 analysts offering their estimates for the company have set an average revenue estimate of $33.29 Million for the current quarter. 6 have an estimated revenue figure of $15.82 Million for the next quarter concluding in March 01, 2021. Year-ago sales stood $44.86 Million and $13.29 Million respectively for this quarter and the next, and analysts expect sales will grow by -25.8% for the current quarter and 19.1% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +0.1% over the past 5 years. Earnings growth for 2020 is a modest +41.8%.
ImmunoGen, Inc. (NASDAQ:IMGN)’s Major holders
Insiders own 0.56% of the company shares, while shares held by institutions stand at 76.45% with a share float percentage of 76.89%. Investors are also buoyed by the number of investors in a company, with ImmunoGen, Inc. having a total of 254 institutions that hold shares in the company. The top two institutional holders are Wellington Management Company, LLP with over 23.08 Million shares worth more than $83.09 Million. As of September 29, 2020, Wellington Management Company, LLP held 12.31% of shares outstanding.
The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 14.19 Million shares as of September 29, 2020. The firm’s total holdings are worth over $51.08 Million and represent 7.57% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Explorer Fund, Inc. and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. As of July 30, 2020, the former fund manager holds about 4.26% shares in the company for having 7985350 shares of worth $32.82 Million while later fund manager owns 5.87 Million shares of worth $33.09 Million as of October 30, 2020, which makes it owner of about 3.13% of company’s outstanding stock.